Coherus BioSciences, Inc. (NASDAQ:CHRS) Q2 2023 Earnings Conference Call August 2, 2023 5:00 PM ET

Company Participants

Marek Ciszewski – Senior Vice President-Investor Relations

Denny Lanfear – President, CEO and Chairman

Paul Reider – Chief Commercial Officer

Theresa LaVallee – Chief Development Officer

Rosh Dias – Chief Medical Officer

McDavid Stilwell – Chief Financial Officer

Conference Call Participants

Robyn Karnauskas – Truist Securities

Michael Nedelcovych – TD Cowen

Douglas Tsao – H.C. Wainwright

Chris Schott – JPMorgan

Ash Verma – UBS

Operator

Good day and thank you for standing by. Welcome to the Coherus Biosciences Second Quarter 2023 Conference Call. At this time all participants are in a listen-only mode. After the speakers' presentation, there will be a question-and-answer session. [Operator Instructions] Please be advised that today's conference is being recorded.

I would now like to hand the conference over to your speaker today, Marek Ciszewski. Please go ahead.

Marek Ciszewski

Thank you, Corey, and good afternoon everyone and thank you for joining us. We issued a press release earlier today announcing our financial results for the second quarter of 2023. This release can be found on the Coherus BioSciences website and is also attached to the Form 8-K that we filed with the SEC today. Today's call includes forward-looking statements regarding Coherus' current expectations about future events. These statements include, but are not limited to, our ability to gain approval for multiple new products and launch them, projections of expenses and revenues, projections of future market share for any product, our expectations for market opportunity for any indication, our expectations about completing the merger with Surface Oncology, timing of our return to being cash flow positive, and expectations about our future portfolio prioritization.

All these forward-looking statements includes substantial risks and uncertainties that are beyond our control and could cause actual results, performance or achievements to differ from those implied by the forward-looking statements. These statements are not guarantees of future performance and are subject to substantial risks and uncertainties. Including the risks and uncertainties about the – our ability to complete the merger with Surface Oncology or realize the anticipated benefits of that transaction that are discussed in our press release that we issued today as well as the documents that we file with the SEC. Forward-looking statements provided on the call today are made as of this date and we undertake no duty to update or revise any forward-looking statements. Second quarter 2023 results are not necessarily indicative of results for future periods. With me on today's call are Denny Lanfear, CEO of Coherus; Dr. Theresa LaVallee, Chief Development Officer; Dr. Rosh Dias, Chief Medical Officer; Paul Reider, Chief Commercial Officer; and McDavid Stilwell, Chief Financial Officer.